Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GOLIMUMAB Cause Maternal exposure timing unspecified? 262 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 262 reports of Maternal exposure timing unspecified have been filed in association with GOLIMUMAB (SIMPONI ARIA). This represents 0.4% of all adverse event reports for GOLIMUMAB.

262
Reports of Maternal exposure timing unspecified with GOLIMUMAB
0.4%
of all GOLIMUMAB reports
168
Deaths
190
Hospitalizations

How Dangerous Is Maternal exposure timing unspecified From GOLIMUMAB?

Of the 262 reports, 168 (64.1%) resulted in death, 190 (72.5%) required hospitalization, and 181 (69.1%) were considered life-threatening.

Is Maternal exposure timing unspecified Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GOLIMUMAB. However, 262 reports have been filed with the FAERS database.

What Other Side Effects Does GOLIMUMAB Cause?

Drug ineffective (17,959) Rheumatoid arthritis (12,272) Pain (11,443) Fatigue (9,626) Off label use (8,764) Alopecia (8,394) Rash (8,331) Joint swelling (8,264) Arthralgia (7,968) Abdominal discomfort (7,902)

What Other Drugs Cause Maternal exposure timing unspecified?

RITUXIMAB (402) METHOTREXATE (350) ADALIMUMAB (343) DICLOFENAC (331) TOCILIZUMAB (327) HYDROXYCHLOROQUINE (309) FOLIC ACID (304) INFLIXIMAB (303) LEFLUNOMIDE (302) SECUKINUMAB (301)

Which GOLIMUMAB Alternatives Have Lower Maternal exposure timing unspecified Risk?

GOLIMUMAB vs GOLODIRSEN GOLIMUMAB vs GONADORELIN GOLIMUMAB vs GONADOTROPHIN, CHORIONIC GOLIMUMAB vs GOSERELIN GOLIMUMAB vs GRAMICIDIN

Related Pages

GOLIMUMAB Full Profile All Maternal exposure timing unspecified Reports All Drugs Causing Maternal exposure timing unspecified GOLIMUMAB Demographics